Dr. Adil Daud graduated the medical school from the Government Medical College Nagpur and completed his residency program at the Indiana University School of Medicine. A fellowship at the Memorial Sloan-Kettering Cancer Center followed soon after that. Dr. Daud is specialized in oncology and board certified in internal medicine and medical oncology. He has been in practice for more than 20 years and is affiliated with the UCSF Medical Center. During his career, he has also contributed to several publications of medical interest.
Government Medical College Nagpur
Indiana University School of Medicine
Memorial Sloan-Kettering Cancer Center
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors.
Daud, A. I.,Ashworth, M. T.,Strosberg, J.,Goldman, J. W.,Mendelson, D.,Springett, G.,Venook, A. P.,Loechner, S.,Rosen, L. S.,Shanahan, F.,Parry, D.,Shumway, S.,Grabows...; J. Clin. Oncol.. 2015 Jan 22.See more >>
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas, A.,Gonzalez, R.,Pavlick, A.,Hamid, O.,Gajewski, T. F.,Daud, A.,Flaherty, L.,Logan, T.,Chmielowski, B.,Lewis, K.,Kee, D.,Boasberg, P.,Yin, M.,Chan, I.,Musib, L.,...; Lancet Oncol.. 2014 Jul 20.See more >>
Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy.
Chen, F. W.,Tseng, D.,Reddy, S.,Daud, A. I.,Swetter, S. M.; JAMA Dermatol. 2014 Aug 22.See more >>
American Association for Cancer Research